^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MYC positive

    i
    Other names: MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
    Entrez ID:
    4609
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients (NCT05529069)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    01/25/2023
    Primary completion :
    04/28/2027
    Completion :
    04/28/2027
    TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2
    |
    TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification
    |
    Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
    Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma (NCT03282396)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    04/22/2024
    Initiation :
    06/08/2020
    Primary completion :
    02/28/2026
    Completion :
    02/28/2026
    TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • NSD2
    |
    TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive
    |
    Imbruvica (ibrutinib)
    Clinical Trial of WB100 on Advanced Solid Tumor (NCT05100251)
    Phase 1
    Zhejiang University
    Recruiting
    Last update posted :
    01/26/2023
    Initiation :
    10/25/2021
    Primary completion :
    10/25/2023
    Completion :
    10/25/2023
    MYC • CA 19-9
    |
    MYC overexpression • MYC expression • MYC positive
    |
    WB100
    Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (NCT01897012)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    01/28/2019
    Initiation :
    07/17/2013
    Primary completion :
    10/31/2018
    Completion :
    11/30/2018
    MYC • BCL2
    |
    MYC positive
    |
    alisertib (MLN8237) • romidepsin